Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Udenafil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mezzion Pharma Clears FUEL-2 Phase 3 Regulatory Milestone
    Mezzion Pharma Clears FUEL-2 Phase 3 Regulatory Milestone

    05 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-pharma-completes-fuel-2-phase-3-regulatory-milestone-302792125.html

    PR NEWSWIRE
    05 Jun 2026
    Share Share
    Mezzion Secures Financing to Advance Phase 3 FUEL-2 Trial
    Mezzion Secures Financing to Advance Phase 3 FUEL-2 Trial

    14 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-secures-strategic-financing-to-support-advancement-of-global-phase-3-fuel-2-trial-in-fontan-patients-302772210.html

    PR NEWSWIRE
    14 May 2026
    Share Share
    Mezzion Gets Pre-IND FDA Feedback on Udenafil in ADPKD
    Mezzion Gets Pre-IND FDA Feedback on Udenafil in ADPKD

    07 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-reports-pre-ind-fda-feedback-on-the-development-of-udenafil-in-adpkd-302765688.html

    PR NEWSWIRE
    07 May 2026
    Share Share
    Mezzion Bolsters Udenafil Exclusivity In Fontan Patients
    Mezzion Bolsters Udenafil Exclusivity In Fontan Patients

    03 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-announces-us-patent-allowance-strengthening-udenafil-exclusivity-in-fontan-patients-302631809.html

    PR NEWSWIRE
    03 Dec 2025
    Share Share
    Udenafil Boosts Exercise Capacity In Fontan Patients Fuel Trial
    Udenafil Boosts Exercise Capacity In Fontan Patients Fuel Trial

    12 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/post-hoc-fuel-trial-analysis-shows-udenafil-significantly-improves-exercise-capacity-in-fontan-patients-with-reduced-baseline-function-302528103.html

    PR NEWSWIRE
    12 Aug 2025
    Share Share
    Mezzion Expands Udenafil Pipeline to Target ADPKD Kidney Market
    Mezzion Expands Udenafil Pipeline to Target ADPKD Kidney Market

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-expands-udenafil-pipeline-to-adpkd-to-target-multi-billion-dollar-kidney-disease-market-302479282.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.